• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.非中性粒细胞减少的念珠菌血症患者中氟康唑浓度-时间曲线下面积/MIC及剂量/MIC比值与死亡率的相关性
Antimicrob Agents Chemother. 2007 Jan;51(1):35-9. doi: 10.1128/AAC.00474-06. Epub 2006 Nov 13.
2
[Antifungal susceptibility profiles of Candida species to triazole: application of new CLSI species-specific clinical breakpoints and epidemiological cutoff values for characterization of antifungal resistance].念珠菌属对三唑类药物的抗真菌药敏谱:应用美国临床和实验室标准协会(CLSI)新的种特异性临床折点和流行病学截断值来表征抗真菌药物耐药性
Mikrobiyol Bul. 2016 Jan;50(1):122-32. doi: 10.5578/mb.10682.
3
Candida and candidaemia. Susceptibility and epidemiology.念珠菌与念珠菌血症。药敏性与流行病学。
Dan Med J. 2013 Nov;60(11):B4698.
4
Association of fluconazole pharmacodynamics with mortality in patients with candidemia.氟康唑药效学与念珠菌血症患者死亡率的关联。
Antimicrob Agents Chemother. 2008 Sep;52(9):3022-8. doi: 10.1128/AAC.00116-08. Epub 2008 Jun 30.
5
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group.一项关于氟康唑与两性霉素B治疗非中性粒细胞减少念珠菌血症患者的随机多中心试验中分离菌株的抗真菌药敏试验。美国国立过敏和传染病研究所真菌病研究组及念珠菌血症研究组。
Antimicrob Agents Chemother. 1995 Jan;39(1):40-4. doi: 10.1128/AAC.39.1.40.
6
International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program.念珠菌属所致血流感染的国际监测:1997年至1999年在哨兵抗菌监测计划中收集的分离株的发生频率以及对氟康唑、伏立康唑和泊沙康唑的体外敏感性
J Clin Microbiol. 2001 Sep;39(9):3254-9. doi: 10.1128/JCM.39.9.3254-3259.2001.
7
Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?来自癌症和非癌症混合患者群体的262株血流酵母菌分离株的抗真菌药敏性:体外对氟康唑的耐药性与真菌血症的结局之间是否存在相关性?
J Infect Chemother. 2000 Dec;6(4):216-21. doi: 10.1007/s101560070006.
8
Species distribution and antifungal susceptibility of Candida bloodstream isolates in Kuwait: a 10-year study.科威特念珠菌血流感染分离株的菌种分布及抗真菌药敏性:一项为期10年的研究。
J Med Microbiol. 2007 Feb;56(Pt 2):255-259. doi: 10.1099/jmm.0.46817-0.
9
Susceptibility profile of 200 bloodstream isolates of Candida spp. collected from Brazilian tertiary care hospitals.从巴西三级护理医院收集的200株念珠菌属血流分离株的药敏谱。
Med Mycol. 2003 Jun;41(3):235-9. doi: 10.1080/1369378031000137198.
10
CHROMagar Candida medium for direct susceptibility testing of yeast from blood cultures.用于血培养中酵母菌直接药敏试验的科玛嘉念珠菌培养基。
J Clin Microbiol. 2005 Apr;43(4):1727-31. doi: 10.1128/JCM.43.4.1727-1731.2005.

引用本文的文献

1
Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for infections.氟康唑在危重症患者中的群体药代动力学分析:参数法和非参数法及 感染的给药模拟。
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0099124. doi: 10.1128/aac.00991-24. Epub 2024 Sep 26.
2
Therapeutic drug monitoring of mycophenolic acid and azole antifungals on two distinct LC-MS/MS instruments.在两种不同的液相色谱-串联质谱仪上对霉酚酸和唑类抗真菌药进行治疗药物监测。
J Mass Spectrom Adv Clin Lab. 2024 Jun 12;33:7-13. doi: 10.1016/j.jmsacl.2024.06.001. eCollection 2024 Aug.
3
Updated antimicrobial dosing recommendations for obese patients.肥胖患者抗菌药物剂量调整的最新推荐。
Antimicrob Agents Chemother. 2024 May 2;68(5):e0171923. doi: 10.1128/aac.01719-23. Epub 2024 Mar 25.
4
Therapeutic Drug Monitoring of Antifungal Agents in Critically Ill Patients: Is There a Need for Dose Optimisation?重症患者抗真菌药物的治疗药物监测:是否需要优化剂量?
Antibiotics (Basel). 2022 May 12;11(5):645. doi: 10.3390/antibiotics11050645.
5
Precision Therapy for Invasive Fungal Diseases.侵袭性真菌病的精准治疗
J Fungi (Basel). 2021 Dec 27;8(1):18. doi: 10.3390/jof8010018.
6
Population Pharmacokinetic Analysis and Dosing Optimization of Prophylactic Fluconazole in Japanese Patients with Hematological Malignancy.日本血液系统恶性肿瘤患者预防性使用氟康唑的群体药代动力学分析及给药优化
J Fungi (Basel). 2021 Nov 16;7(11):975. doi: 10.3390/jof7110975.
7
Model-Informed Drug Development for Anti-Infectives: State of the Art and Future.基于模型的抗感染药物研发:现状与未来。
Clin Pharmacol Ther. 2021 Apr;109(4):867-891. doi: 10.1002/cpt.2198. Epub 2021 Mar 9.
8
Role and Interpretation of Antifungal Susceptibility Testing for the Management of Invasive Fungal Infections.抗真菌药敏试验在侵袭性真菌感染管理中的作用及解读
J Fungi (Basel). 2020 Dec 30;7(1):17. doi: 10.3390/jof7010017.
9
Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically Ill Patients.基于危重症患者氟康唑药代动力学的氟康唑给药方案优化用于侵袭性念珠菌病的预防和治疗
Antimicrob Agents Chemother. 2021 Feb 17;65(3). doi: 10.1128/AAC.01554-20.
10
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.危重症成人患者的抗菌治疗药物监测:立场文件。
Intensive Care Med. 2020 Jun;46(6):1127-1153. doi: 10.1007/s00134-020-06050-1. Epub 2020 May 7.

本文引用的文献

1
Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.氟康唑治疗开始时间对念珠菌血症患者死亡率有影响:一项多机构研究。
Clin Infect Dis. 2006 Jul 1;43(1):25-31. doi: 10.1086/504810. Epub 2006 May 16.
2
Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.氟康唑与念珠菌的解释性折点再探讨:抗真菌药敏试验未来的蓝图。
Clin Microbiol Rev. 2006 Apr;19(2):435-47. doi: 10.1128/CMR.19.2.435-447.2006.
3
Treatment of Candida infection: a view from the trenches!念珠菌感染的治疗:来自临床一线的观点!
Curr Opin Infect Dis. 2005 Dec;18(6):490-5. doi: 10.1097/01.qco.0000191516.43792.61.
4
Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.在获得血培养阳性结果之前延迟念珠菌血流感染的经验性治疗:医院死亡率的一个潜在危险因素。
Antimicrob Agents Chemother. 2005 Sep;49(9):3640-5. doi: 10.1128/AAC.49.9.3640-3645.2005.
5
Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.氟康唑的最低抑菌浓度(MIC)以及氟康唑剂量与MIC的比值与念珠菌血症患者的治疗反应相关。
Antimicrob Agents Chemother. 2005 Aug;49(8):3171-7. doi: 10.1128/AAC.49.8.3171-3177.2005.
6
The integration of pharmacokinetics and pathogen susceptibility data in the design of rational dosing regimens.在合理给药方案设计中整合药代动力学和病原体敏感性数据。
Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):781-8. doi: 10.1358/mf.2004.26.10.872560.
7
The effects of renal impairment on the pharmacokinetics and safety of fosfluconazole and fluconazole following a single intravenous bolus injection of fosfluconazole.单次静脉推注磷氟康唑后,肾功能损害对磷氟康唑和氟康唑药代动力学及安全性的影响。
Br J Clin Pharmacol. 2004 Jun;57(6):773-84. doi: 10.1111/j.1365-2125.2004.02073.x.
8
Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection.念珠菌血流感染患者中与氟康唑耐药及短期生存相关的临床因素。
Eur J Clin Microbiol Infect Dis. 2004 May;23(5):380-8. doi: 10.1007/s10096-004-1128-2. Epub 2004 Apr 27.
9
Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.临床实践中12年的氟康唑应用:念珠菌血流感染分离株的菌种分布及氟康唑敏感性的全球趋势
Clin Microbiol Infect. 2004 Mar;10 Suppl 1:11-23. doi: 10.1111/j.1470-9465.2004.t01-1-00844.x.
10
Guidelines for treatment of candidiasis.念珠菌病治疗指南。
Clin Infect Dis. 2004 Jan 15;38(2):161-89. doi: 10.1086/380796. Epub 2003 Dec 19.

非中性粒细胞减少的念珠菌血症患者中氟康唑浓度-时间曲线下面积/MIC及剂量/MIC比值与死亡率的相关性

Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia.

作者信息

Pai Manjunath P, Turpin Robin S, Garey Kevin W

机构信息

University of New Mexico, Albuquerque, New Mexico, USA.

出版信息

Antimicrob Agents Chemother. 2007 Jan;51(1):35-9. doi: 10.1128/AAC.00474-06. Epub 2006 Nov 13.

DOI:10.1128/AAC.00474-06
PMID:17101684
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1797664/
Abstract

The present study tested in vitro susceptibility of Candida bloodstream isolates to fluconazole to determine if the ratio of the fluconazole area under the concentration-time curve (AUC) or weight-normalized daily dose (dose(wn)) to MIC correlated with mortality. Fluconazole susceptibility and outcome data were determined for 77 patients with a positive Candida blood culture between 2002 and 2005. The most commonly isolated Candida species were C. albicans (64%), C. glabrata (14%), C. parapsilosis (8%), C. tropicalis (6%), and C. lusitaniae (4%). Only two isolates were classified as fluconazole resistant by the CLSI M27-A2 method. Fluconazole MICs were highest against C. glabrata relative to other Candida species. Overall the crude mortality assessed at hospital discharge was 19.4% (n = 15). Mortality rates by species were as follows: C. albicans, 16.3%; C. glabrata, 36.4%; C. parapsilosis, 0%; C. tropicalis, 0%; C. lusitaniae, 33.3%. A mortality rate of 50% was noted among patients infected with nonsusceptible isolates (MIC > or = 16 microg/ml) compared to 18% for patients infected with susceptible (MIC < or = 8 microg/ml) isolates (P = 0.17). The fluconazole dose(wn)/MIC (24-h) values were significantly higher for the 62 survivors (13.3 +/- 10.5 [mean +/- standard deviation]) compared to the 15 nonsurvivors (7.0 +/- 8.0) (P = 0.03). The fluconazole AUC/MIC (24 h) values also trended higher for survivors (775 +/- 739) compared to nonsurvivors (589 +/- 715) (P = 0.09). These data support the dose-dependent properties of fluconazole. Underdosing fluconazole against less-susceptible Candida isolates has the potential to increase the risk of mortality associated with candidemia.

摘要

本研究检测了念珠菌血流分离株对氟康唑的体外敏感性,以确定氟康唑浓度 - 时间曲线下面积(AUC)或体重标准化每日剂量(剂量(wn))与最低抑菌浓度(MIC)的比值是否与死亡率相关。测定了2002年至2005年间77例念珠菌血培养阳性患者的氟康唑敏感性和转归数据。最常分离出的念珠菌种类为白色念珠菌(64%)、光滑念珠菌(14%)、近平滑念珠菌(8%)、热带念珠菌(6%)和葡萄牙念珠菌(4%)。根据CLSI M27 - A2方法,只有两株分离株被归类为氟康唑耐药。相对于其他念珠菌种类,氟康唑对光滑念珠菌的MIC最高。总体而言,出院时评估的粗死亡率为19.4%(n = 15)。各菌种的死亡率如下:白色念珠菌,16.3%;光滑念珠菌,36.4%;近平滑念珠菌,0%;热带念珠菌,0%;葡萄牙念珠菌,33.3%。感染不敏感分离株(MIC≥16μg/ml)的患者死亡率为50%,而感染敏感分离株(MIC≤8μg/ml)的患者死亡率为18%(P = 0.17)。62名幸存者的氟康唑剂量(wn)/MIC(24小时)值(13.3±10.5[平均值±标准差])显著高于15名非幸存者(7.0±8.0)(P = 0.03)。幸存者的氟康唑AUC/MIC(24小时)值(775±739)也比非幸存者(589±715)更高(P = 0.09)。这些数据支持氟康唑的剂量依赖性特性。对敏感性较低的念珠菌分离株给予氟康唑不足剂量有可能增加念珠菌血症相关的死亡风险。